Case todayBrokenLate SEC filing · Nov 17, 2026The case · mixed · Nov 17, 2026Own ABPO if ABPO is a distressed biotech call option on whether its TetraBi antibody platform, led by ABP-102 and backed by Celltrion, can reach clinical validation before financing risk overwhelms common shareholders.4 conditions2 holding · 2 weakeningNext resultsNot scheduledNo date filed yet

ABPO at a glance

The past year

Chart

−90.3% $0.53, close Nov 16

From the highest close
−92.5%
Vs the 200-day average
+69.5%
Nov 14, 2025Daily close, Abpro HoldingsNov 16, 2026

Short interest

History

15,840 shares

Since the last report
−1.6%
Days to cover
1.0 day
Settled
Oct 30, 2026

Insider buying, 7 days

Filings

None filed this week

Form 4s filed
Nov 12 – Nov 18

Understand the Business

Why the Stock Moved

Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.

ABPO price history

Latest price$0.53Today+$0.00 (+0.75%)
ABPO +49.58%S&P 500 -4.78%Since first plotted close
4 hours

Loading recent earnings…

Investment thesis

What must happen next

4 MATERIAL PROPOSITIONS
  • Celltrion’s continued commitment is the critical external validation mechanism for ABP-102, because Abpro’s platform economics depend on partner-funded milestones rather than recurring commercial sales.HoldingMateriality: High

    Item 1 Business states ABP-102 is being developed and commercialized through a worldwide strategic partnership with Celltrion. If Celltrion remains engaged, ABPO has a credible path to non-dilutive value creation; if Celltrion steps back, the platform loses its most important validation and funding channel.

    Watch: Celltrion terminates, materially narrows, or stops funding the ABP-102 collaboration.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    Item 1 Business states ABP-102 is being developed and commercialized through a worldwide strategic partnership with Celltrion.

    Open source ↗
  • Abpro must secure outside capital or partner cash before the pipeline can create value, because liquidity—not market demand for an approved product—is the immediate gating constraint.WeakeningMateriality: High

    FY2025 cash was only $82,000 at year-end. If financing arrives on acceptable terms, shareholders retain exposure to ABP-102; if it does not, dilution, restructuring, or insolvency can erase the option value.

    Watch: Nasdaq denies the delisting appeal, further limiting access to institutional capital.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    FY2025 cash was only $82,000 at year-end.

    Open source ↗
  • Management must keep the operating model lean enough for partner milestones or financings to bridge the company to clinical data; a clinical-spend ramp without new funding would overwhelm the balance sheet.HoldingMateriality: Medium

    GAAP annual operating cash flow improved to negative $6.006 million in FY2025 from negative $9.030 million in FY2024. Burn discipline extends the life of the ABP-102 option; loss of discipline forces distressed financing before any scientific proof point can re-rate the company.

    Watch: ABP-102 clinical trial initiation materially increases CRO, manufacturing, and regulatory cash needs before financing is secured.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    GAAP annual operating cash flow improved to negative $6.006 million in FY2025 from negative $9.030 million in FY2024.

    Open source ↗
  • The OTC Pink trading status and negative equity position make capital access a central operating risk, so per-share value depends on restoring market credibility or finding strategic capital outside the public market.WeakeningMateriality: Medium

    Item 1 Business states Abpro was delisted from Nasdaq effective February 23, 2026 and currently trades on the OTC Pink Limited Market. A relisting or strategic financing could preserve upside for common holders; continued capital-market impairment shifts value toward creditors and new money.

    Watch: Nasdaq denies the company’s appeal of the delisting determination.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    Item 1 Business states Abpro was delisted from Nasdaq effective February 23, 2026 and currently trades on the OTC Pink.

    Open source ↗
Full investment case & evidence

Loading the original research archive…

Original research

Celltrion’s continued commitment is the critical external validation mechanism for ABP-102, because Abpro’s platform economics depend on partner-funded milestones rather than recurring commercial sales. If Celltrion remains engaged, ABPO has a credible path to non-dilutive value creation; if Celltrion steps back, the platform loses its most important validation and funding channel.

Abpro must secure outside capital or partner cash before the pipeline can create value, because liquidity—not market demand for an approved product—is the immediate gating constraint. If financing arrives on acceptable terms, shareholders retain exposure to ABP-102; if it does not, dilution, restructuring, or insolvency can erase the option value.

Management must keep the operating model lean enough for partner milestones or financings to bridge the company to clinical data; a clinical-spend ramp without new funding would overwhelm the balance sheet. Burn discipline extends the life of the ABP-102 option; loss of discipline forces distressed financing before any scientific proof point can re-rate the company.

The OTC Pink trading status and negative equity position make capital access a central operating risk, so per-share value depends on restoring market credibility or finding strategic capital outside the public market. A relisting or strategic financing could preserve upside for common holders; continued capital-market impairment shifts value toward creditors and new money.

All standing thesis claims
Original report summary

ABPO is a distressed biotech call option on whether its TetraBi antibody platform, led by ABP-102 and backed by Celltrion, can reach clinical validation before financing risk overwhelms common shareholders.

Evidence assessed Nov 17, 2026. Expand each conclusion for its evidence and what would change it. Thesis evidence—not a buy or sell recommendation.

Bull case and bear case

Bull case and bear case for Abpro Holdings

Where the evidence on Abpro Holdings disagrees: Mixed on the latest evidence (Nov 17, 2026). Of its 4 thesis points, 2 holding and 2 weakening.

Bull case: what the evidence supports

  • Celltrion’s continued commitment is the critical external validation mechanism for ABP-102, because Abpro’s platform economics depend on partner-funded milestones rather than recurring commercial sales.

    sec.gov ↗

  • Management must keep the operating model lean enough for partner milestones or financings to bridge the company to clinical data; a clinical-spend ramp without new funding would overwhelm the balance sheet.

    sec.gov ↗

Bear case: what the evidence questions

  • Abpro must secure outside capital or partner cash before the pipeline can create value, because liquidity—not market demand for an approved product—is the immediate gating constraint.

    sec.gov ↗

  • The OTC Pink trading status and negative equity position make capital access a central operating risk, so per-share value depends on restoring market credibility or finding strategic capital outside the public market.

    sec.gov ↗

Thesis-Break Engine

What has broken in Abpro Holdings’s thesis

Each break OptimistFi flagged on Abpro Holdings, dated — with what has historically followed the same kind of break across the market, not a forecast for Abpro Holdings.

peers+16%-43%-12%12 mo agonow+6 mo
Daily price, then where similar breaks led across the market: the typical -12% path vs comparable companies over six months, inside the middle-half range (+16% to -43%). A base rate, not a forecast.
  • Late SEC filingcondition set before this filing

    Across all companies, this kind of break has happened 4,811 times before. Those stocks trailed comparable companies by a median of 12% over the next six months, and 52% of them trailed it by 10 points or more.

How the Thesis-Break Engine works →Historical outcomes are measured against comparable companies after past breaks of the same kind, across all companies. Not a prediction.

MARKET + FINANCIAL SNAPSHOT

The numbers behind the thesis

Sourced from filings and market data

What Changed

  1. Mixed
    Director or principal officer change.

    Abpro Holdings filed an SEC 8-K on 2026-09-01: Director or principal officer change. It is a dated development that tests the current thesis.

  2. Mixed
    Director or principal officer change.

    Abpro Holdings filed an SEC 8-K on 2026-08-25: Director or principal officer change. It is a dated development that tests the current thesis.

  3. Mixed
    Delisting notice or listing-rule failure.

    Abpro Holdings filed an SEC 8-K on 2026-06-04: Delisting notice or listing-rule failure. It is a dated development that tests the current thesis.

Risks / falsifiers

What could break the thesis

  • Celltrion terminates, materially narrows, or stops funding the ABP-102 collaboration.
  • Nasdaq denies the delisting appeal, further limiting access to institutional capital.
  • ABP-102 clinical trial initiation materially increases CRO, manufacturing, and regulatory cash needs before financing is secured.
  • Nasdaq denies the company’s appeal of the delisting determination.

ABPO news

Loading headlines…

Financial statements

ABPO income statement

Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.

ABPO: quick answers

What is ABPO's short interest?
As of October 30, 2026, 15,840 ABPO shares were sold short, down 1.6% from the count before. At the stock's average daily volume that is 1.0 day to cover. FINRA publishes the count twice a month. ABPO short interest history
ScoutJUST THIS STORY

LET’S MAKE THIS USEFUL · 1 OF 5

How would you like me to explain this?

Tell me what you want from this read. Start with a quick note, then adjust the details. Your other stories stay as they are.

We’ll remember your view of this story. The published article stays unchanged.

THIS STORY’S READING VIEWStandard · The whole picture

Clear explanations with context. Both sides of the evidence.